Johnson & Johnson (JNJ)

NYSE
Currency in USD
163.63
+0.61(+0.37%)
Closed
After Hours
163.31-0.32(-0.20%)
JNJ Scorecard
Full Analysis
Has raised its dividend for 54 consecutive years
Fair Value
Day's Range
162.48164.13
52 wk Range
140.68169.99
Johnson & Johnson is currently considered to be trading at Fair valueExplore our list of undervalued stocks for hidden opportunities
Key Statistics
Edit
Prev. Close
163.02
Open
163
Day's Range
162.48-164.13
52 wk Range
140.68-169.99
Volume
17.05M
Average Volume (3m)
8.92M
1-Year Change
5.06%
Book Value / Share
29.69
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
JNJ Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
169.07
Upside
+3.32%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with low price volatility
Show more

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Employees
138100

Johnson & Johnson SWOT Analysis


Oncology Powerhouse
Johnson & Johnson's oncology portfolio drives growth, with projections exceeding $50 billion in sales by 2030, showcasing the company's dominance in this crucial sector.
Biosimilar Battleground
Delve into JNJ's strategy to counter the impending Stelara biosimilar challenge, balancing pipeline strength against market pressures in a evolving competitive landscape.
Pipeline Potential
Explore nipocalimab's promise as a potential blockbuster, with JNJ projecting peak annual sales surpassing $5 billion across multiple autoimmune indications.
Analyst Perspectives
Price targets range from $152 to $215, reflecting diverse views on JNJ's ability to navigate challenges while capitalizing on growth opportunities in healthcare.
Read full SWOT analysis

Johnson & Johnson Earnings Call Summary for Q3/2024

  • Operational sales grew 6.3% to $22.5B; U.S. sales up 7.6%, international up 4.6%. Full-year guidance raised for third consecutive quarter.
  • Adjusted operational EPS guidance raised to $9.91 for 2024. Innovative Medicine sales exceeded $14B for two consecutive quarters.
  • MedTech sales reached $7.9B (6.4% growth). Abiomed reported 16.3% growth. DARZALEX surpassed $3B in quarterly sales.
  • $1.25B expense for NM26 antibody and talc litigation. Challenges in Asia Pacific, particularly China, due to procurement and economic pressures.
  • Q4 outlook: ~5% adjusted operational growth expected. Improved performance anticipated in Cardiovascular and Vision businesses.
Last Updated: 15/10/2024, 19:30
Read Full Transcript

Compare JNJ to Peers and Sector

Metrics to compare
JNJ
Peers
Sector
Relationship
P/E Ratio
28.0x4.8x−0.5x
PEG Ratio
−0.48−0.530.00
Price/Book
5.5x4.3x2.6x
Price / LTM Sales
4.4x3.3x3.0x
Upside (Analyst Target)
1.7%62.2%54.9%
Fair Value Upside
Unlock23.0%9.8%Unlock

Analyst Ratings

9 Buy
13 Hold
0 Sell
Ratings:
22 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 169.07
(+3.32% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 5.84%
Dividend Yield
3.04%
Industry Median 1.79%
Annualised payout
4.96
Paid quarterly
5-Years Growth
+5.54%
Growth Streak

Earnings

Latest Release
Jan 22, 2025
EPS / Forecast
2.04 / 2.02
Revenue / Forecast
22.52B / 22.46B
EPS Revisions
Last 90 days

People Also Watch

93.11
MRK
-1.71%
115.50
XOM
-0.35%
156.82
QCOM
-0.72%
85.98
WMT
+0.20%
516.85
UNH
+1.09%

FAQ

What Is the J&J (JNJ) Premarket Price Today?

The J&J (JNJ) premarket price is . Premarket price change units: . Premarket percentage change: . Premarket volume: . Current date: 22 Mar 2025. Previous close: 163.02

What Stock Exchange Does J&J Trade On?

J&J is listed and trades on the NYSE stock exchange.

What Is the Stock Symbol for J&J?

The stock symbol for J&J is "JNJ."

What Is the J&J (JNJ) Afterhours Price Today? (Afterhours variable test: ) Current Date: 22 Mar 2025

After hours price: . After hours price change (units): . Price change percentage:

What Is the J&J Market Cap?

As of today, J&J market cap is 394.32B.

What is J&J Earnings Per Share?

The J&J EPS is 5.84.

What Is the Next J&J Earnings Date?

J&J will release its next earnings report on 14 Apr 2025.

From a Technical Analysis Perspective, Is JNJ a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.